- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01156259
30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
July 1, 2010 updated by: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
The purpose of this study is to determine whether 30Gy Involved-field Radiotherapy (IFRT) is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The best proper doses of IFRT in combined modality treatments (CMT) for localized DLBCL is still undetermined.
Existing treatment guidelines recommend 40Gy or above as the standard treatment dosage.
However, there were large-scaled clinical trials implying smaller doses such as 30Gy may be equivalent effective.
Lowering radiation doses can decrease treatment toxicities and radiotherapy-induced diseases, which has been conformed by HD13 study for Hodgkin's Lymphoma.
It may even retain the truth when modern era radiation techniques are involved and especially in patients achieving CR after chemotherapy.
A comprehensive, prospective dose-comparing study is needed.
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: YeXiong Li, MD
- Phone Number: 8610-87788860
- Email: yexiong3@yahoo.com.cn
Study Contact Backup
- Name: Shunan qi, MD
- Phone Number: 8610-87725547
- Email: qishunan@yahoo.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Shunan qi, MD
- Phone Number: 8610-87725547
- Email: qishunan@yahoo.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- biopsy-proved Diffuse Large B cell lymphoma
- nonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
- provide written informed consent
- Complete regression after chemotherapy
- Considerable to CT simulation and 3D CRT or IMRT
- Performance status 0-2 WHO criteria;life expectation>6 months
- negative for human immunodeficiency virus syndrome (HIV)
- Minimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies
Exclusion Criteria:
- primary mediastinal large B cell lymphoma
- dermatological lymphoma
- testicular lymphoma
- primary central nerve system lymphoma
- prior RT
- history of low-grade lymphoma congestive
- history of heart failure (CHF; New York Heart Association [NYHA] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase > 2.5 times the upper limit of normal, bilirubin > 50 ), renal insufficiency (serum creatinine > 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 30 Gy
|
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
|
Active Comparator: 40 Gy
|
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
disease free survival
Time Frame: five years
|
five years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall survival
Time Frame: five years
|
five years
|
acute treatment toxicity
Time Frame: up to 16 weeks
|
up to 16 weeks
|
late treatment toxicity
Time Frame: five years
|
five years
|
treatment failure type
Time Frame: five years
|
five years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Yexiong Li, MD, Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Anticipated)
April 1, 2015
Study Completion (Anticipated)
May 1, 2015
Study Registration Dates
First Submitted
June 29, 2010
First Submitted That Met QC Criteria
July 1, 2010
First Posted (Estimate)
July 2, 2010
Study Record Updates
Last Update Posted (Estimate)
July 2, 2010
Last Update Submitted That Met QC Criteria
July 1, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CH-LYM-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on 3D-CRT based Involved Field Radiotherapy
-
Di DengRecruitingRecurrent Follicular LymphomaChina
-
Yonsei UniversityRecruitingRecurrent Ovarian CancerKorea, Republic of
-
Trans Tasman Radiation Oncology GroupPeter MacCallum Cancer Centre, Australia; Australasian Leukaemia and Lymphoma...UnknownNon-gastric Marginal Zone LymphomaAustralia
-
University College, LondonThe Christie NHS Foundation TrustActive, not recruiting
-
Children's Cancer Group, ChinaShanghai Children's Medical CenterRecruitingHodgkin LymphomaChina
-
Emory UniversityTerminatedBladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the BladderUnited States
-
Cancer Institute and Hospital, Chinese Academy...CompletedThoracic Neoplasms | Non-small Cell Lung CancerChina
-
International Extranodal Lymphoma Study Group (IELSG)Active, not recruitingPrimary Mediastinal B-cell LymphomaNorway, United Kingdom, Italy, Switzerland, Czechia, United States, China, Argentina, Canada, Germany, Poland, Portugal, Sweden, Ukraine
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States